????6. 諾華公司

????? 2013年研發(fā)支出：99億美元

????? 占收入的百分比：16.8%

????諾華公司（Novartis）的研發(fā)投入規(guī)模在醫(yī)療保健行業(yè)位居第二。2013年，研發(fā)支出占該公司收入的比重接近17%。諾華有200多個項目處于臨床開發(fā)階段，其中138個是藥物項目。Zykadia是該公司的重大研發(fā)成果之一，這是一種選擇性間變性淋巴瘤激酶抑制劑，用于治療肺癌。諾華8月份所公布的心力衰竭臨床試驗藥物LCZ696的數(shù)據(jù)顯示，該藥療效好于目前的最佳治療手段。今年10月，美國食品藥品監(jiān)督管理局（FDA）顧問委員會全票支持批準將諾華新藥AIN457（secukinumab）用于治療中重度牙菌斑。

????6. Novartis

????? R&D spending in 2013: $9.9 billion

????? As a percentage of revenue: 16.8%

????As the second-biggest health care spender, Novartis invested nearly 17% of its revenues into R&D in 2013 and has more than 200 projects in clinical development, including 138 in pharmaceuticals. Among the big discoveries from its R&D program was the drug Zykadia, which treats patients with a certain form of lung cancer called anaplastic lymphoma and, in August, the company presented data on its drug LCZ696, an investigational heart failure medicine, showing it was superior to the current best treatments. And in October, an advisory committee to the FDA approved unanimously to support the approval AIN457 (secukinumab) for the treatment of moderate-to-severe dental plaque.